Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma

NEXT STORY
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
PREV STORY
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery

-I.V. CR845 achieved statistical significance for the study’s primary endpoint of pain relief over ...

author_avatar
NASDAQ Market News

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

author_avatar
NASDAQ Market News

Monalizumab to advance to Phase III in head and neck cancer

author_avatar
NASDAQ Market News